Literature DB >> 8836814

Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver.

F Oesch1, M Arand, M S Benedetti, M G Castelli, P Dostert.   

Abstract

Important species differences have been reported concerning the induction properties of rifampicin towards enzymes of the P-450 superfamily. Mice, rabbits and humans are far more responsive than rats and guinea pigs. In the present study a strong induction of cytochrome P-450 3A-dependent enzyme activities was observed in female rat liver microsomes after high dose treatment (> or = 250 mg/kg/day for 9 days) with rifampicin, resulting in an up to 30-fold enhanced hydroxylation rate of testosterone in the 2 beta-, 6 beta- and 15 beta-position in vitro. Other cytochrome P-450 isozyme-selective reactions were not, or only marginally, affected. A steep increase in cytochrome P-450 3A activity on a moderate elevation of the dose administered, together with the previously observed lack of efficient induction with doses below 200 mg/kg/day demonstrated that there is a threshold in enzyme induction by rifampicin. For rifabutin such a threshold was not apparent. Induction by rifabutin showed an isoenzyme-selectivity profile similar to that produced by rifampicin, but the maximally achievable induction of cytochrome P-450 3A by rifabutin was about two-fold lower compared with rifampicin. Rifampicin and rifabutin enhanced the glucuronidation of 1-naphthol, 4-hydroxybiphenyl and beta-estradiol by a factor of two to three. The potential implications of the enzyme induction by rifampicin derivatives in terms of possible drug-drug interactions are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8836814     DOI: 10.1093/jac/37.6.1111

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping.

Authors:  Bettina Link; Manuel Haschke; Nathalie Grignaschi; Michael Bodmer; Yvonne Zysset Aschmann; Markus Wenk; Stephan Krähenbühl
Journal:  Br J Clin Pharmacol       Date:  2008-04-11       Impact factor: 4.335

2.  Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

Authors:  Michael J Dolton; John E Ray; Sharon C-A Chen; Kingsley Ng; Lisa Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

3.  Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients.

Authors:  K D Gallicano; J Sahai; V K Shukla; I Seguin; A Pakuts; D Kwok; B C Foster; D W Cameron
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

4.  Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients.

Authors:  Elinore F McCance-Katz; David E Moody; Sudha Prathikanti; Gerald Friedland; Petrie M Rainey
Journal:  Drug Alcohol Depend       Date:  2011-05-19       Impact factor: 4.492

5.  Evaluation of drug-drug interactions with fesoterodine.

Authors:  Bimal Malhotra; Richard Sachse; Nolan Wood
Journal:  Eur J Clin Pharmacol       Date:  2009-04-04       Impact factor: 2.953

6.  Metabolism and elimination of quinine in healthy volunteers.

Authors:  Rajaa A Mirghani; Urban Hellgren; Leif Bertilsson; Lars L Gustafsson; Orjan Ericsson
Journal:  Eur J Clin Pharmacol       Date:  2003-08-12       Impact factor: 2.953

7.  Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.

Authors:  Michael J Dolton; Roger J M Brüggemann; David M Burger; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

8.  The influence of P-glycoprotein expression in the standard treatment of Helicobacter pylori infection in Sprague Dawley rats.

Authors:  Noor Safwah Damanhuri; Endang Kumolosasi; Marhanis Salihah Omar; Amirul Faiz Abd Razak; Ahmad Hasnan Mansor
Journal:  Daru       Date:  2021-01-06       Impact factor: 3.117

9.  A multi-center preclinical study of gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function.

Authors:  Anastassia Karageorgis; Stephen C Lenhard; Brittany Yerby; Mikael F Forsgren; Serguei Liachenko; Edvin Johansson; Mark A Pilling; Richard A Peterson; Xi Yang; Dominic P Williams; Sharon E Ungersma; Ryan E Morgan; Kim L R Brouwer; Beat M Jucker; Paul D Hockings
Journal:  PLoS One       Date:  2018-05-17       Impact factor: 3.240

10.  Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review.

Authors:  Tom G Jacobs; Elin M Svensson; Victor Musiime; Pablo Rojo; Kelly E Dooley; Helen McIlleron; Rob E Aarnoutse; David M Burger; Anna Turkova; Angela Colbers
Journal:  J Antimicrob Chemother       Date:  2020-12-01       Impact factor: 5.790

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.